APDN - Applied DNA Sciences, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Stony Brook,
United States
Type: Equity
APDN price evolution
APDN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11.19 | $3.9 | $4.11 | |
| Short term investments | ||||
| Net receivables | $0.36 | $0.51 | $0.41 | $0.45 |
| Inventory | $0.44 | $0.47 | $0.34 | $0.38 |
| Total current assets | $8.05 | $11.84 | $4.36 | $4.59 |
| Long term investments | ||||
| Property, plant & equipment | $1.29 | $1.4 | $1.36 | $1.66 |
| Goodwill & intangible assets | $2.7 | $2.7 | $2.92 | |
| Total noncurrent assets | $4.85 | $4.81 | $5.32 | |
| Total investments | ||||
| Total assets | $12.79 | $16.69 | $9.18 | $9.91 |
| Current liabilities | ||||
| Accounts payable | $1.17 | $2.44 | $2.05 | $2.02 |
| Deferred revenue | $0.25 | $0.25 | $0.28 | |
| Short long term debt | $0.53 | $0.52 | $0.51 | |
| Total current liabilities | $2.4 | $3.03 | $2.62 | $2.59 |
| Long term debt | $0.33 | $0.47 | $0.61 | |
| Total noncurrent liabilities | $1.43 | $6.73 | $3.2 | |
| Total debt | $0.87 | $0.99 | $1.12 | |
| Total liabilities | $3.65 | $4.46 | $9.35 | $5.78 |
| Shareholders' equity | ||||
| Retained earnings | -$309.67 | -$306.38 | -$308.26 | -$303.63 |
| Other shareholder equity | ||||
| Total shareholder equity | $12.39 | -$0.05 | $4.23 | |
| (in millions $) | 30 Oct 2024 | 31 Dec 2023 | 30 Oct 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7.9 | $15.31 | $6.65 | |
| Short term investments | ||||
| Net receivables | $0.36 | $0.26 | $3.07 | $2.8 |
| Inventory | $0.44 | $0.33 | $0.6 | $1.37 |
| Total current assets | $8.05 | $8.13 | $19.94 | $11.3 |
| Long term investments | ||||
| Property, plant & equipment | $1.29 | $2.08 | $2.22 | $3.02 |
| Goodwill & intangible assets | $2.7 | |||
| Total noncurrent assets | $5.53 | $2.32 | $3.12 | |
| Total investments | ||||
| Total assets | $12.79 | $13.65 | $22.27 | $14.42 |
| Current liabilities | ||||
| Accounts payable | $1.17 | $2.27 | $1.74 | $2.99 |
| Deferred revenue | $0.27 | $0.56 | $0.28 | |
| Short long term debt | $0.5 | |||
| Total current liabilities | $2.4 | $2.85 | $4.19 | $3.27 |
| Long term debt | $0.74 | |||
| Total noncurrent liabilities | $5.93 | $5.17 | $0.03 | |
| Total debt | $1.24 | |||
| Total liabilities | $3.65 | $8.78 | $9.35 | $3.3 |
| Shareholders' equity | ||||
| Retained earnings | -$309.67 | -$302.45 | -$292.5 | -$284.12 |
| Other shareholder equity | ||||
| Total shareholder equity | $4.95 | $12.91 | $11.11 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.8 | |||
| Cost of revenue | $0.55 | |||
| Gross Profit | $0.25 | |||
| Operating activities | ||||
| Research & development | $0.91 | |||
| Selling, general & administrative | $2.68 | |||
| Total operating expenses | $3.59 | |||
| Operating income | -$3.35 | |||
| Income from continuing operations | ||||
| EBIT | $1.88 | |||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | $1.88 | |||
| Income (for common shares) | $1.88 | |||
| (in millions $) | 30 Oct 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.43 | $13.37 | $18.17 | $9.03 |
| Cost of revenue | $7.83 | $13.12 | $4.1 | |
| Gross Profit | $1.02 | $5.53 | $5.05 | $4.93 |
| Operating activities | ||||
| Research & development | $3.74 | $3.93 | $3.77 | |
| Selling, general & administrative | $12.75 | $15.1 | $12.61 | |
| Total operating expenses | $15.04 | $16.49 | $19.02 | $18.04 |
| Operating income | -$10.95 | -$13.97 | -$13.11 | |
| Income from continuing operations | ||||
| EBIT | -$9.95 | -$8.28 | -$14.3 | |
| Income tax expense | ||||
| Interest expense | $0.18 | -$0.01 | -$0.01 | |
| Net income | ||||
| Net income | -$7.23 | -$9.95 | -$8.27 | -$14.29 |
| Income (for common shares) | -$9.95 | -$8.38 | -$14.29 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $1.88 | -$4.47 | -$1.11 | |
| Operating activities | ||||
| Depreciation | $0.13 | $0.19 | $0.3 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.03 | $0.17 | $0.34 | |
| Total cash flows from operations | -$3.49 | -$3.21 | -$3.76 | |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.01 | ||
| Investments | ||||
| Total cash flows from investing | -$0.41 | -$0.02 | -$0.01 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $10.81 | $2.93 | $0.05 | |
| Net borrowings | ||||
| Total cash flows from financing | $13.4 | $10.81 | $3.02 | -$0.04 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.72 | $7.29 | -$0.21 | -$3.79 |
| (in millions $) | 30 Oct 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$9.95 | -$8.27 | -$14.29 | |
| Operating activities | ||||
| Depreciation | $1.36 | $1.29 | $0.84 | |
| Business acquisitions & disposals | -$1.06 | |||
| Stock-based compensation | $1.03 | $2.52 | $1.67 | |
| Total cash flows from operations | -$6.22 | -$8.98 | -$13.39 | |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.49 | -$2.55 | |
| Investments | ||||
| Total cash flows from investing | -$0.41 | -$1.1 | -$0.49 | -$2.55 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $18.13 | $16.37 | ||
| Net borrowings | -$1.67 | |||
| Total cash flows from financing | $13.4 | $18.13 | $14.7 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.72 | -$7.31 | $8.66 | -$1.23 |
News
Fundamentals
| Market cap | $2.06M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 10.31M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.36 |
| Quick ratio | 3.17 |